Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study
BCMA-CAR-T therapy confers short-term remission and survival benefits in relapsed/refractory plasma cell leukemia (R/R PCL). However, the definitive value of allogeneic hematopoietic stem cell transplantation (allo-HSCT) awaits validation in large-sample prospective studies.
Authors
- Shilin Gan
- Yuelu Guo
- Miaomiao Cao (ORCID: https://orcid.org/0000-0002-4863-4454)
- Yimeng Dou (ORCID: https://orcid.org/0000-0003-2202-6263)
- Rui Liu (ORCID: https://orcid.org/0000-0001-7573-3346)
- Kai Hu (ORCID: https://orcid.org/0000-0003-1436-9522)
- Danyang Li (ORCID: https://orcid.org/0000-0002-4795-5766)
- Zhonghua Fu
- Fan Yang
- Biping Deng
- Xiaoyan Ke
- Bian Wei
- Alex H. Chang
- Lixia Ma
Institutions
- Accenture (Switzerland) (CH)
- Ministry of Education (KR)
- Lymphoma Study Association (FR)
- Biostatistical Consulting (United States) (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3389/fimmu.2026.1756209
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00